{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016647","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.269105+00:00","generated_at":"2026-06-24T01:04:48.571855+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Monte Rosa Q2 2022 net loss $26.5M; IND submitted for MRT-2359","bullets":["Net loss of $26.5M for Q2 2022, compared to $18.4M in Q2 2021.","Cash, equivalents, and marketable securities of $299.5M as of June 30, 2022; expected runway into late 2024.","R&D expenses of $20.9M in Q2 2022 vs $14.6M in Q2 2021, driven by MRT-2359 advancement and platform expansion.","Submitted IND for MRT-2359 (GSPT1 degrader) for Myc-driven solid tumors; Phase 1/2 trial planned for Q4 2022.","Progress on CDK2 and NEK7 programs toward development candidate nominations."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016647","json":"https://secwatch.observer/filing/0000950170-22-016647.json","markdown":"https://secwatch.observer/filing/0000950170-22-016647.md","text":"https://secwatch.observer/filing/0000950170-22-016647.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095017022016647/0000950170-22-016647-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095017022016647/glue-20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:04:48.571855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}